GSK Probes Allegedly Fake Data Produced by Employees
June 6th, 2013 // 1:11 pm @ jmpickett
Latest FDA and cGMP Compliance News
GSK is currently investigating if a scientific paper from 2010 was written by several R&D scientists in China who used fabricated data.
GSK also is putting at least one employee at this R&D center in China on leave while the probe is conducted. The paper appeared in Nature Medicine, and studied the role of a protein known as Interleukin 7 receptor to treat autoimmune disease and has the name of a dozen employees of GSK.
Download Your Free Sample – the Latest FDA 483 and Warning Letter Reports!
The internal investigation became public this week after Chinese blogs wrote about what was happening. This resulted in three top GSK scientists to send out an internal memo to hopefully stop the speculation.
They stated that they are doing an internal investigation about the alleged issues with the scientific paper. They stated that they take the faked data allegations seriously because research is very important to the work the company does.
A GSK spokeswoman stated this week that the company is doing an internal investigation into some alleged issues regarding the scientific paper.
This is the second time in the last month that a global pharmaceutical company has started a probe over published clinical trial results involving their employees. Novartis recently had to admit that two of its employees in Japan had some level of involvement in their clinical trials for a heart drug. They were started by investigators but were supposed to be fully independent studies.
